---
title: "Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Product comparison"
description: "Formulary evidence on Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Product comparison. Topics: Competing products named by the sponsor, Ficerafusp alfa plus pembrolizumab: population definition and phase 1b HPV-negative results, Pembrolizumab-based regimens in HPV-negative disease: outcomes cited by the ficerafusp alfa phase 1b report, Pembrolizumab monotherapy: approved first-line indication, and 17 further topics. 21 evidence topics quoted from 21 sources."
canonical: "https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/product-information-and-disease-description/product-comparison"
published: "2026-11-15T21:46:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Product comparison

<a id="heading-2.1.2.14"></a>

## 2.1.2.14 Product comparison

<a id="topic-2.1.2.14-1"></a>

### Competing products named by the sponsor

> “We expect to compete with currently commercially available therapies for the treatment of HNSCC, including pembrolizumab (marketed as Keytruda by Merck & Co); the combination of pembrolizumab, platinum chemotherapy and 5-fluorouracil; and the combination of cetuximab (marketed as Erbitux by Eli Lilly & Company in the U.S. and by Merck KGaA outside of the U.S.), platinum chemotherapy and 5-fluorouracil.”
> “In addition, there are numerous companies that are developing new treatments for HNSCC, including but not limited to Akeso, Inc., AstraZeneca PLC, AVEO Pharmaceuticals, Inc., BioAtla Inc., BioNTech SE, Corbus Pharmaceuticals Holdings Inc., GSK plc, InhibRx Biosciences, Inc., Johnson & Johnson, Merus N.V. (a Genmab A/S company), PDS Biotechnology Corp, Pyxis Oncology, Inc., and Rakuten Medical, Inc.”
> “The key factors that will ultimately affect the success of our bifunctional therapies, if approved, are likely their safety, efficacy, convenience and cost.”

Source: [Bicara Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026022010/bcax-20251231.htm)

<a id="topic-2.1.2.14-2"></a>

### Ficerafusp alfa plus pembrolizumab: population definition and phase 1b HPV-negative results

> “granted Breakthrough Therapy Designation (BTD) to ficerafusp alfa in combination with pembrolizumab for the first line (1L) treatment of patients with metastatic or with unresectable, recurrent (R/M) head and neck squamous cell carcinoma (HNSCC) whose tumors express programmed death-ligand 1 with combined positive score (CPS) ≥1, excluding human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma”

Source: [Bicara Therapeutics breakthrough therapy designation announcement (2025)](https://ir.bicara.com/news-releases/news-release-details/bicara-therapeutics-announces-ficerafusp-alfa-granted)

> “Twelve oropharyngeal tumors were classified as HPV-positive, whereas all oral cavity, hypopharynx, and larynx tumors were considered HPV-negative per current clinical standard.”
> “In efficacy-evaluable patients with HPV-negative (n = 28) or HPV-positive (n = 11) tumors, confirmed ORRs were 54% (complete response in 21%) and 27%, respectively. In the HPV-negative subgroup, median DOR was 21.7 months (95% CI, 6.0 to not estimable [NE]), median PFS was 9.9 months (95% CI, 4.4 to 22.7), and median OS was 21.3 months (95% CI, 9.9 to NE).”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-2.1.2.14-3"></a>

### Pembrolizumab-based regimens in HPV-negative disease: outcomes cited by the ficerafusp alfa phase 1b report

> “However, in retrospective real-world studies in the United States and the United Kingdom, median OS with pembrolizumab monotherapy in patients with HPV-negative tumors was approximately 9 months.”
> “In phase II studies assessing 1L treatment with anti–PD-1 agents (nivolumab or pembrolizumab) in combination with cetuximab (anti-EGFR) in all-comer R/M HNSCC populations, ORRs were 37% and 45%, respectively; median DOR with pembrolizumab plus cetuximab was 13.1 months, and median OS with nivolumab plus cetuximab in patients with HPV-negative tumors was 10.6 months.”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-2.1.2.14-4"></a>

### Pembrolizumab monotherapy: approved first-line indication

> “KEYTRUDA, as a single agent, is indicated for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-authorized test”

Source: [Merck KEYTRUDA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s191lblCorrected.pdf)

<a id="topic-2.1.2.14-5"></a>

### Pembrolizumab monotherapy: KEYNOTE-048 survival and response in the CPS 1 or greater population at 4-year follow-up

> “The median OS was 14.9 months (95% CI, 11.5 to 20.6) for pembrolizumab alone versus 10.8 months (95% CI, 8.8 to 12.8) for cetuximab-chemotherapy in the PD-L1 CPS ≥ 20 population (HR, 0.61; 95% CI, 0.46 to 0.81; nominal one-sided P = .00034), 12.3 months (95% CI, 10.8 to 14.8) versus 10.4 months (95% CI, 9.0 to 11.7) in the CPS ≥ 1 population (HR, 0.74; 95% CI, 0.61 to 0.89; nominal one-sided P = .00080)”
> “The ORR was 23.3% (11 CR/20 PR) for pembrolizumab alone versus 36.1% (4 CR/40 PR) for cetuximab-chemotherapy in the PD-L1 CPS ≥ 20 population, 19.1% (15 CR/34 PR) versus 34.9% (7 CR/82 PR) in the CPS ≥ 1 population, and 16.9% (15 CR/36 PR) versus 36.0% (8 CR/100 PR) in the total population”

Source: [Harrington et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9902012/)

<a id="topic-2.1.2.14-6"></a>

### Pembrolizumab plus platinum and fluorouracil: approved first-line indication

> “KEYTRUDA, in combination with platinum and fluorouracil (FU), is indicated for the first-line treatment of patients with metastatic or with unresectable, recurrent head and neck squamous cell carcinoma (HNSCC).”

Source: [Merck KEYTRUDA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s191lblCorrected.pdf)

<a id="topic-2.1.2.14-7"></a>

### Pembrolizumab plus platinum and fluorouracil: KEYNOTE-048 survival and response at 4-year follow-up

> “The median OS was 14.7 months (95% CI, 10.3 to 19.3) for pembrolizumab-chemotherapy versus 11.1 months (95% CI, 9.2 to 13.0) for cetuximab-chemotherapy in the PD-L1 CPS ≥ 20 population (HR, 0.62; 95% CI, 0.46 to 0.84; nominal one-sided P = .00082), 13.6 months (95% CI, 10.7 to 15.5) versus 10.6 months (95% CI, 9.1 to 11.7) in the CPS ≥ 1 population (HR, 0.64; 95% CI, 0.53 to 0.78; nominal one-sided P = .00001), and 13.0 months (95% CI, 10.9 to 14.7) versus 10.7 months (95% CI, 9.3 to 11.7) in the total population”
> “The ORR was 43.7% (13 CR/42 PR) for pembrolizumab-chemotherapy versus 38.2% (4 CR/38 PR) for cetuximab-chemotherapy in the PD-L1 CPS ≥ 20 population, 37.2% (17 CR/73 PR) versus 35.7% (7 CR/77 PR) in the CPS ≥ 1 population, and 36.3% (18 CR/84 PR) versus 36.3% (8 CR/93 PR) in the total population”

Source: [Harrington et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9902012/)

<a id="topic-2.1.2.14-8"></a>

### KEYNOTE-048 population: HPV status and PD-L1 distribution

> “Eligible patients were age ≥ 18 years with previously untreated R/M squamous cell carcinoma of the oropharynx (known p16 expression), oral cavity, hypopharynx, or larynx, which was incurable by local therapy”
> “Random assignment was stratified by PD-L1 expression (tumor proportion score ≥ 50% v < 50%), p16 expression for oropharyngeal cancer (positive v negative), and Eastern Cooperative Oncology Group performance status (0 v 1).”

Source: [Harrington et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9902012/)

> “Twenty-two percent of patients’ tumors were HPV-positive, 23% had PD-L1 TPS ≥50%, and 95% had Stage IV disease”
> “Eighty-five percent of patients’ tumors had PD-L1 expression of CPS ≥1 and 43% had CPS ≥20.”

Source: [Merck KEYTRUDA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s191lblCorrected.pdf)

<a id="topic-2.1.2.14-9"></a>

### Cetuximab plus platinum and fluorouracil (EXTREME): approved first-line indication and population

> “in combination with platinum-based therapy with fluorouracil for the first-line treatment of patients with recurrent locoregional disease or metastatic SCCHN.”
> “Thirty-four percent of patients had oropharyngeal, 25% laryngeal, 20% oral cavity, and 14% hypopharyngeal primary tumors.”

Source: [ImClone ERBITUX prescribing information (2021)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf)

<a id="topic-2.1.2.14-10"></a>

### Cetuximab plus platinum and fluorouracil (EXTREME): efficacy results

| Outcome | Result |
| --- | --- |
| Median overall survival, cetuximab with platinum-based therapy and fluorouracil (n=222), months | “10.1” |
| Median overall survival, platinum-based therapy and fluorouracil (n=220), months | “7.4” |
| Overall survival hazard ratio (95% CI) | “0.80 (0.64, 0.98)” |
| Median progression-free survival, cetuximab arm, months | “5.5” |
| Median progression-free survival, control arm, months | “3.3” |
| Objective response rate, cetuximab arm | “35.6%” |
| Objective response rate, control arm | “19.5%” |

Source: [ImClone ERBITUX prescribing information (2021)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf)

<a id="topic-2.1.2.14-11"></a>

### Petosemtamab plus pembrolizumab: LiGeR-HN1 phase 3 topline results

> “Based on the first interim analysis assessed by an independent data monitoring committee (IDMC), treatment with the petosemtamab combination demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS), reducing the risk of death by 50%, and objective response rate (ORR) versus pembrolizumab [OS: HR 0.50 (95% CI, 0.37, 0.67); p<0.0001; ORR: odds ratio 3.17 (95% CI, 2.06, 4.89; p<0.0001), meeting its dual primary endpoints, regardless of HPV status.”
> “LiGeR-HN1 (NCT06525220) is a randomized, open-label, global, multicenter Phase 3 study evaluating the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ HNSCC.”
> “The safety profile of petosemtamab when administered in combination with pembrolizumab was generally well tolerated and consistent with the previously reported safety profiles of the individual agents (petosemtamab and pembrolizumab).”

Source: [Genmab LiGeR-HN1 interim analysis announcement (2026)](https://ir.genmab.com/news-releases/news-release-details/genmab-announces-statistically-significant-clinically-meaningful)

<a id="topic-2.1.2.14-12"></a>

### Petosemtamab plus pembrolizumab: LiGeR-HN1 eligibility and HPV classification

> “The eligible HNSCC primary tumor locations are oropharynx, oral cavity, hypopharynx, and larynx.”
> “HNSCC patients eligible to receive pembrolizumab as 1L monotherapy with tumors expressing PD-L1, CPS ≥1.”
> “HNSCC patients should not have had previous systemic therapy administered in the incurable recurrent or metastatic setting”
> “Patient has a primary tumor site of nasopharynx, or sinonasal carcinoma (any histology)”

Source: [ClinicalTrials.gov NCT06525220](https://clinicaltrials.gov/study/NCT06525220)

> “p16 status is measured only in patients with oropharyngeal tumors; all other tumor locations are designated as p16 negative for the purposes of stratification.”
> “Randomization will be stratified based on p16 status (positive vs. negative) and PD-L1 CPS (<20 vs. ≥20), as determined by central laboratory testing, and ECOG PS (0 vs. 1).”

Source: [Machiels et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12218485/)

<a id="topic-2.1.2.14-13"></a>

### Petosemtamab plus pembrolizumab: phase 2 first-line cohort

> “In the 1L combination arm, treatment with petosemtamab plus pembrolizumab achieved a median overall survival (OS) of 28.2 months, associated with an overall response rate (ORR) of 63% and median progression free survival (mPFS) of 9.0 months in efficacy-evaluable patients (n=43), including a complete response (CR) rate of 19%.”
> “As of May 15, 2026, median duration of follow-up was 25.5 months; clinical activity was observed across combined positive PD L-1 expression levels and p16 subgroups.”
> “In the first-line combination arm, 45 patients were treated with 1500 mg of petosemtamab every two weeks plus 400 mg of pembrolizumab every six weeks until disease progression or unacceptable toxicity.”
> “Infusion-related reactions occurred in 38% of patients (7% Grade 3-4), and all resolved.”

Source: [Genmab petosemtamab phase 2 update announcement (2026)](https://ir.genmab.com/news-releases/news-release-details/genmab-announces-updated-phase-2-data-demonstrating-more-two)

<a id="topic-2.1.2.14-14"></a>

### Amivantamab plus pembrolizumab: OrigAMI-4 cohort 2, first-line, p16-positive oropharyngeal cancer excluded

> “Cohort 2 of the phase 1b/2 OrigAMI-4 (NCT06385080) study enrolled participants with previously untreated R/M HNSCC and PD-L1 combined positive score ≥1.”
> “Patients with p16-positive oropharyngeal cancer and prior anti-EGFR or anti-PD-(L)1 therapy were excluded.”
> “At a median follow-up of 13.6 months, confirmed ORR was 59% (95% CI, 42-74), with 7 (18%) complete responses.”
> “Median PFS was 7.7 months (95% CI, 5.0-NR); median OS was NR.”

Source: [Kao et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42742405/)

> “In Cohort 2 of the OrigAMI-4 study, treatment with subcutaneous amivantamab plus pembrolizumab, administered every three weeks, demonstrated a confirmed overall response rate of 56 percent (22/39; 95 percent confidence interval [CI], 40-72)”
> “At a median follow-up of 10.4 months (range, 1.6-12.5), 46 percent of patients remained on treatment.”

Source: [Johnson & Johnson OrigAMI-4 cohort 2 announcement (2026)](https://www.jnj.com/media-center/press-releases/rybrevant-faspro-amivantamab-and-hyaluronidase-lpuj-plus-immunotherapy-shows-strong-clinical-benefit-with-56-percent-overall-response-rate-in-first-line-recurrent-or-metastatic-head-and-neck-cancer)

<a id="topic-2.1.2.14-15"></a>

### Amivantamab plus pembrolizumab and carboplatin: OrigAMI-4 cohort 5, first-line

> “Response rates were assessed separately in patients with HPV-associated OPSCC (n=7) and patients with all other forms of HNSCC (n=22), given known differences in how these patient populations respond to EGFR-targeted bispecifics.”
> “Among the 22 patients with forms of HNSCC other than HPV-associated OPSCC, the confirmed ORR was 77 percent (95 percent confidence interval [CI], 55-92), including complete responses in 14 percent and partial responses in 64 percent.”
> “Median overall survival was not reached, and 77 percent of patients were alive at one year. The remaining seven patients had HPV-associated OPSCC, with an ORR of 29 percent (95 percent CI, 4-71).”
> “Cohort 5 of the OrigAMI-4 study evaluated RYBREVANT FASPRO, administered every three weeks, in combination with pembrolizumab and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma receiving first-line treatment whose tumors tested positive for programmed death-ligand 1 (PD-L1), with a combined positive score (CPS) of 1 or greater.”

Source: [Johnson & Johnson OrigAMI-4 cohort 5 announcement (2026)](https://www.jnj.com/media-center/press-releases/rybrevant-faspro-amivantamab-and-hyaluronidase-lpuj-combination-demonstrates-77-overall-response-rate-in-first-line-treatment-of-patients-with-advanced-head-and-neck-cancer)

<a id="topic-2.1.2.14-16"></a>

### Amivantamab plus pembrolizumab and carboplatin: OrigAMI-5 phase 3 design and population

> “Have histologically or cytologically confirmed recurrent/metastatic (R/M) HNSCC that is considered incurable by local therapies: a. eligible primary tumor locations are the oral cavity, oropharynx, hypopharynx, or larynx; b. Must not have a primary tumor site of nasopharynx or primary tumor of unknown location”
> “Human papillomavirus (HPV) status must be known for participants with primary tumor location in oropharynx via p16 test, HPV DNA test, or high-risk HPV in situ hybridization (ISH). Any known p16, HPV DNA, or high-risk HPV ISH status of tumor must be negative”
> “Be treatment-naive for systemic therapy in the R/M setting”

Source: [ClinicalTrials.gov NCT07276399](https://clinicaltrials.gov/study/NCT07276399)

> “the ongoing Phase 3 OrigAMI-5 study (NCT07276399) assessing subcutaneous amivantamab with carboplatin and pembrolizumab as a first-line treatment in patients with HPV-unrelated recurrent or metastatic disease, regardless of PD-L1 expression”

Source: [Johnson & Johnson OrigAMI-4 cohort 2 announcement (2026)](https://www.jnj.com/media-center/press-releases/rybrevant-faspro-amivantamab-and-hyaluronidase-lpuj-plus-immunotherapy-shows-strong-clinical-benefit-with-56-percent-overall-response-rate-in-first-line-recurrent-or-metastatic-head-and-neck-cancer)

<a id="topic-2.1.2.14-17"></a>

### Amivantamab and hyaluronidase: accelerated approval in previously treated disease

> “RYBREVANT FASPRO is indicated as a single agent for the treatment of adult patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose disease has progressed on or after platinum-based chemotherapy and an anti-PD-(L)1 antibody.”
> “Limitations of use: RYBREVANT FASPRO is not indicated as a treatment for patients with oropharyngeal squamous cell carcinoma (OPSCC) that is human papillomavirus (HPV)-associated (i.e., by p16 IHC).”
> “This indication is approved under accelerated approval based on overall response rate and duration of response.”
> “The primary efficacy population included 102 patients with recurrent or metastatic HNSCC. Patients with HPV-associated OPSCC based on p16 testing results (only required for OPSCC), were excluded from the primary efficacy population.”

Source: [Janssen RYBREVANT FASPRO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761433s002lbl.pdf)

| Outcome | RYBREVANT FASPRO (N=102) |
| --- | --- |
| Overall response rate (95% CI) | “42% (32%, 52%)” |
| Complete response | “15%” |
| Partial response | “28%” |
| Patients with duration of response of 6 months or longer | “56%” |

Source: [Janssen RYBREVANT FASPRO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761433s002lbl.pdf)

<a id="topic-2.1.2.14-18"></a>

### Enfortumab vedotin plus pembrolizumab: EV-202 first-line cohort

> “Eligible patients had R/M HNSCC, programmed cell death ligand 1 (PD-L1) combined positive score (CPS) ≥1, and no prior systemic therapy in the R/M setting.”
> “The primary analysis included 41 patients.”
> “Sixteen patients achieved a response, and cORR was 39% [95% confidence interval (CI), 24.2–55.5]. The complete response rate was 9.8%.”
> “The median PFS was 5.1 months (95% CI, 3.5–not estimable).”
> “In patients with p16-positive oropharyngeal cancer ( n = 11), the cORR was 81.8%, in contrast to 23.3% in patients with non-HPV–associated disease ( n = 30).”
> “b For oropharyngeal squamous cell carcinoma only, patients without oropharyngeal cancer were considered HPV–negative.”
> “Patients also did not undergo any testing to confirm their HPV status.”

Source: [Swiecicki et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13473864/)

<a id="topic-2.1.2.14-19"></a>

### HPV16-positive first-line combinations with pembrolizumab: BNT113

> “Patients who present histologically confirmed recurrent or metastatic HPV16+ HNSCC that is considered incurable by local therapies.”
> “Patients must not have had prior systemic anticancer therapy administered in the incurable recurrent or metastatic setting.”

Source: [ClinicalTrials.gov NCT04534205](https://clinicaltrials.gov/study/NCT04534205)

<a id="topic-2.1.2.14-20"></a>

### HPV16-positive first-line combinations with pembrolizumab: PDS0101

> “HPV16 tumor positivity (central testing).”
> “Tumor PD-L1 expression defined as a CPS ≥ 1 using the FDA- approved pembrolizumab (KEYTRUDA®) assay (local testing).”
> “The study is being discontinued solely based on financial constraints and is not related to the safety of study participants, the investigational product, PDS0101, nor the conduct of the study.”

Source: [ClinicalTrials.gov NCT06790966](https://clinicaltrials.gov/study/NCT06790966)

<a id="topic-2.1.2.14-21"></a>

### HPV-negative disease after PD-1 inhibitor and platinum: ficlatuzumab plus cetuximab

> “Participants with oropharyngeal cancer will be required to have proof of p16 negative status submitted on the basis of a pathology report”
> “Participants must have failed prior therapy with an anti-PD-1/PD-L1 ICI and with platinum-based chemotherapy administered in combination or sequentially, in either the locally advanced or R/M setting.”

Source: [ClinicalTrials.gov NCT06064877](https://clinicaltrials.gov/study/NCT06064877)

Additional sources: [Tahara et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40262400/); [Vermorken et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/18784101/)

## Related pages
- [Ficerafusp alfa (BCA101): First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Terms and abbreviations](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/terms-and-abbreviations.md)
- [Ficerafusp alfa (BCA101): First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/executive-summary.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Product information and disease description](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/product-information-and-disease-description.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Clinical evidence](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/clinical-evidence.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Economic information and modeling report](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/economics) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/economics.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: References](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/references) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/references.md)
